Human trial
Orexin A primary study · PMID 24406723
14 subjects with narcolepsy and cataplexy in a blinded crossover study.
Reported findings. Researchers assessed sleep, wakefulness and attention after intranasal orexin-A.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Very small disease-specific experiment; it does not establish a cognitive or energy benefit in healthy users.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.